机构地区: 北京大学公共卫生学院流行病与卫生统计学系,北京100191
出 处: 《中国疫苗和免疫》 2017年第4期471-476,共6页
摘 要: 手足口病(Hand,foot and mouth disease,HFMD)是一种急性传染病,高发人群是婴幼儿。2015年12月国家食品药品监督管理总局批准两家国产肠道病毒71型(EV71)灭活疫苗上市,该疫苗很可能使中国大陆成为第一个用疫苗预防儿童HFMD的地区。本研究分析评价了临床研究中6-35月龄儿童接种EV71疫苗后的免疫原性,以及疫苗上市后需要关注的问题。 Hand,foot and mouth disease(HFMD) is an acute infectious disease that commonly infects infants and young children. In December 2015,the China Food and Drug Administration(CFDA) firstly licensed the inactivated enterovirus 71(EV71) vaccine produced by two domestic manufacturers. This vaccine is likely to make China to be the first region of using a vaccine to prevent HFMD in children.This paper reviewed the immunogenicity of EV71 vaccine among children aged 6-35 months in clinical trials,and some issues to be concerned after its marketing.